In this study, LINC01198 is identified highly upregulated and acts as driving factor, which associates with TAOK1/TAOK2 to activate Hippo pathway and transcriptionally induce IL-1B expression for supporting melanoma resistance against vemurafenib. Here, TAOK2 is linked to melanoma.